United Therapeutics Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by United Therapeutics Corporation (UTHR) on July 22, 2026. The filing reports a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation.
Material Changes
- Board Expansion: The Board of Directors increased its size to 13 members.
- New Appointment: Victor Dzau, M.D., was appointed as a new director effective July 22, 2026.
- Committee Assignments: Dr. Dzau will not serve on any Board committee initially.
- Related Transactions: No transactions exceeding $120,000 involving Dr. Dzau have occurred since the beginning of the last fiscal year.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for Dr. Dzau under the 2026 Stock Incentive Plan, granted on July 22, 2026:
- Initial Grant: 380 restricted stock units (RSUs) and 1,190 stock options.
- Pro-Rata Grant: 350 RSUs and 1,110 stock options representing the remainder of the 2026-2027 Board service year.
- Agreements: Dr. Dzau entered into the Company's standard indemnification agreement for directors and executive officers.
The filing includes a press release (Exhibit 99.1) regarding the appointment but explicitly states that this information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the total number of Board members is now 13.
- Confirm the specific vesting schedules for the 730 RSUs and 2,300 stock options granted to Dr. Dzau.
- Review the definitive proxy statement filed on April 29, 2026, for full details on the Director Compensation Program.
- Check for future filings regarding Dr. Dzau's potential assignment to Board committees.